Seeing is believing:anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy

查看全文 作　　者：Shuguang [1]Tan;Catherine W-H [1]Zhang;George F [1]Gao

机构地区：[1]CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing,China and 2ImmuFuCell Biotechnology Co.,Ltd.,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》索引2016年第1卷第1期,共4页

基　　金：This work was supported by the Ministry of Science and Technology of China(973 program:2013CB531502);the National Natural Science Foundation of China(NSFC;31390432 and 31500722). 摘　　要：Structural immunology,focusing on structures of host immune related molecules,enables the immunologists to see what the molecules look like,and more importantly,how they work together.Antibody-based PD-1/PD-L1 blockade therapy has achieved brilliant successes in clinical applications.The recent breakthrough of the complex structures of checkpoint blockade antibodies with their counterparts,pembrolizumab with PD-1 and avelumab with PD-L1,have made it clear how these monoclonal antibodies compete the binding of PD-1/PD-L1 and function to blockade the receptor-ligand interaction.Herein,we summarize the structural findings of these two reports and look into the future for how this information would facilitate the development of more efficient PD-1/PD-L1 targeting antibodies,small molecule drugs,and other protein or non-protein inhibitors. 关键词：ANTIBODIES MONOCLONAL DRUGS

相关文献

参考文献（42）
引证文献（9）
耦合文献（22）

参考文献(42)

引证文献(9)

耦合文献(22)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Seeing is believing:anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy

参考文献(42)

引证文献(9)

耦合文献(22)

用户提示